Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14691321 | 0.83 | LMNA (0.32) | KCNJ1LMNAPRKDCUHRF1 | |
| SCHEMBL6628386 | 0.80 | NOS3 (0.44) | KCNJ1 | |
| SCHEMBL29952328 | 0.80 | NOS3 (0.44) | KCNJ1 | |
| SCHEMBL13724582 | 0.79 | UHRF1 (0.54) | KCNJ1LMNAUHRF1 | |
| SCHEMBL1179602 | 0.79 | HDAC8 (0.31) | UHRF1 | |
| SCHEMBL29955122 | 0.77 | GRIA1 (0.38) | KCNJ1LMNA | |
| SCHEMBL21358365 | 0.76 | LMNA (0.37) | LMNA | |
| SCHEMBL336343 | 0.75 | CYP1A2 (0.34) | KCNJ1 | |
| SCHEMBL8685644 | 0.75 | ERN1 (0.34) | KCNJ1LMNA | |
| SCHEMBL29186887 | 0.75 | KCNJ1 (0.33) | KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4688785-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | Beone Medicines I GmbH (CH) | 2026-02-11 | — | — | EP | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4577546-A1 | NAPHTHYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES | Enliven Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| CN-120129682-A | Naphthyridine compounds for inhibition of RAF kinase | 英莱汶公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| WO-2025096751-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-2507230-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES | Syngenta Participations AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-20120238517-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238517-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238517-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOAZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012080284-A2 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011067272-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067272-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | KCNJ1 3109/4885LMNA 3643/4885EGLN2 782/4885 |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | KCNJ1 3415/4885LMNA 2964/4885EGLN2 2180/4885 |
| US-20120238517-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOAZOLINE DERIVATIVES | CHRM1, ACHE, CHRM2 | KCNJ1 485/4885LMNA 1405/4885EGLN2 3511/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | KCNJ1 3817/4885LMNA 3805/4885EGLN2 960/4885 |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | BMI1, EZH2, SUZ12 | KCNJ1 3713/4885LMNA 3710/4885EGLN2 651/4885 |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | KCNJ1 2069/4885LMNA 4551/4885EGLN2 2316/4885 |
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | S1PR5, CLN6, SNCA | KCNJ1 383/4885LMNA 1560/4885EGLN2 1010/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | KCNJ1 4070/4885LMNA 3312/4885EGLN2 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.